2017
Comparison of Survival Outcomes Among Human Papillomavirus–Negative cT1-2 N1-2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy: An Observational Study
Kelly JR, Park HS, An Y, Contessa JN, Yarbrough WG, Burtness BA, Decker R, Husain Z. Comparison of Survival Outcomes Among Human Papillomavirus–Negative cT1-2 N1-2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy: An Observational Study. JAMA Oncology 2017, 3: 1107-1111. PMID: 28056116, PMCID: PMC5824218, DOI: 10.1001/jamaoncol.2016.5769.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaHPV-negative oropharyngeal squamous cell carcinomaNegative oropharyngeal squamous cell carcinomaMultivariable Cox regressionPrimary surgical resectionOverall survivalUpfront surgerySurgical resectionObservational studyChemoradiation therapySurgical patientsAdjuvant CRTSurvival outcomesCox regressionNational Cancer Data BaseOropharyngeal squamous cell cancerDefinitive chemoradiation therapyMost surgical patientsConcurrent chemoradiation therapyHPV-positive diseaseMargin-negative resectionOptimal patient selectionPrimary treatment modalityUpfront surgical resectionKaplan-Meier analysisRole of Adjuvant Treatment in Esophageal Cancer With Incidental Pathologic Node Positivity
Gao SJ, Park HS, Corso CD, Rutter CE, Kim AW, Johung KL. Role of Adjuvant Treatment in Esophageal Cancer With Incidental Pathologic Node Positivity. The Annals Of Thoracic Surgery 2017, 104: 267-274. PMID: 28456393, DOI: 10.1016/j.athoracsur.2017.01.092.Peer-Reviewed Original ResearchConceptsMargin-positive patientsSurgical resectionEsophageal cancer patientsMargin-negative patientsAdjuvant treatmentChemoradiation therapyOverall survivalCarcinoma patientsCancer patientsMultivariable Cox regression analysisNational Cancer Data BaseSquamous cell carcinoma patientsPathologic nodal involvementPathologic node positivityConcurrent chemoradiation therapyAdjuvant chemoradiation therapyCell carcinoma patientsEsophageal carcinoma patientsCox regression analysisFurther prospective studiesOptimal adjuvant treatmentLog-rank testKaplan-Meier estimationAdjuvant chemotherapyN0 patients
2015
Concurrent Chemoradiation Therapy Is Associated With Improved Survival Compared to Radiation Therapy Alone for Anaplastic Gliomas
Yeboa D, Rutter C, Park H, Lester-Coll N, Corso C, Mancini B, Bindra R, Yu J. Concurrent Chemoradiation Therapy Is Associated With Improved Survival Compared to Radiation Therapy Alone for Anaplastic Gliomas. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: s168. DOI: 10.1016/j.ijrobp.2015.07.404.Peer-Reviewed Original ResearchConcurrent chemoradiation therapyChemoradiation therapyAnaplastic gliomasRadiation therapyTherapyGliomasPractice Patterns of Concurrent Chemoradiation Therapy Compared to Radiation Therapy Alone for Low Grade Gliomas
Yeboa D, Park H, Rutter C, Mancini B, Corso C, Lester-Coll N, Bindra R, Yu J. Practice Patterns of Concurrent Chemoradiation Therapy Compared to Radiation Therapy Alone for Low Grade Gliomas. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e73. DOI: 10.1016/j.ijrobp.2015.07.730.Peer-Reviewed Original ResearchConcurrent chemoradiation therapyLow-grade gliomasChemoradiation therapyPractice patternsRadiation therapyGrade gliomasTherapyGliomasSurvival Benefit of Concurrent Chemoradiation Therapy for Unresected Glioblastoma Multiforme in the Temozolomide Era
Kole A, Yeboa D, Rutter C, Lester-Coll N, Corso C, Mancini B, Bindra R, Yu J, Park H. Survival Benefit of Concurrent Chemoradiation Therapy for Unresected Glioblastoma Multiforme in the Temozolomide Era. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e64. DOI: 10.1016/j.ijrobp.2015.07.706.Peer-Reviewed Original ResearchConcurrent chemoradiation therapyChemoradiation therapySurvival benefitTemozolomide eraGlioblastoma multiformePatients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non–Small-Cell Lung Cancer
Wang EH, Rutter CE, Corso CD, Decker RH, Wilson LD, Kim AW, Yu JB, Park HS. Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non–Small-Cell Lung Cancer. Journal Of Thoracic Oncology 2015, 10: 937-943. PMID: 25738221, DOI: 10.1097/jto.0000000000000519.Peer-Reviewed Original ResearchConceptsDefinitive concurrent chemoradiation therapyConcurrent chemoradiation therapyHigh-volume facilitiesNon-small cell lung cancerStage III NSCLC patientsCell lung cancerOverall survivalNSCLC patientsLung cancerStage III non-small cell lung cancerHigher Charlson-Deyo comorbidity scoresCharlson-Deyo comorbidity scoreNational Cancer Data BaseCox proportional hazards regressionFacility case volumeImproved overall survivalAdvanced nodal stageDefinitive concurrent chemoradiationKaplan-Meier analysisPopulation-based survivalMultivariable logistic regressionProportional hazards regressionRisk of deathIntensity-modulated radiotherapyAcademic affiliation